Scalper1 News
With 40 biotech IPOs completed this year, seven more are planned as the health care sector overall continues to dominate new issues. Biotech companies account for half the 14 initial public offerings planned for this week. The best performing IPO last week was Sage Therapeutics (SAGE), an early-stage biotech developing treatments for life-threatening epileptic seizures. Sage priced at 18, the high end of its upwardly revised range, and closed at Scalper1 News
Scalper1 News